Profile data is unavailable for this security.
About the company
Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed an expansive and modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. Its platform enables it to rapidly and effectively find, screen, and select tools with the highest targetability, specificity, and efficiency in order to develop them into genetic medicine.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2016
- Employees237.00
- LocationMetagenomi Inc5959 Horton St, Floor 7EMERYVILLE 94608United StatesUSA
- Phone+1 (510) 871-4880
- Fax+1 (302) 636-5454
- Websitehttps://metagenomi.co/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fennec Pharmaceuticals Inc | 44.95m | 2.84m | 181.70m | 36.00 | 181.84 | 59.80 | 63.89 | 4.04 | 0.0366 | 0.0366 | 1.62 | 0.1112 | 0.9878 | 1.15 | 7.52 | -- | 6.25 | -73.43 | 7.37 | -84.32 | 96.19 | -- | 6.33 | -383.28 | 6.72 | 1.84 | 0.9087 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| Rigel Pharmaceuticals Inc | 120.35m | -19.80m | 181.73m | 147.00 | -- | -- | -- | 1.51 | -1.13 | -1.13 | 6.90 | -1.81 | 0.9623 | 0.9241 | 4.23 | 818,680.30 | -15.83 | -28.82 | -30.14 | -47.26 | 93.22 | 97.88 | -16.45 | -35.76 | 1.17 | -2.91 | 2.13 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Adverum Biotechnologies Inc | 0.00 | -112.90m | 182.25m | 121.00 | -- | 0.9997 | -- | -- | -10.23 | -10.23 | 0.00 | 8.78 | 0.00 | -- | -- | 0.00 | -41.55 | -36.39 | -47.50 | -39.04 | -- | -- | -- | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| G1 Therapeutics Inc | 84.04m | -30.59m | 184.03m | 100.00 | -- | 6.63 | -- | 2.19 | -0.6146 | -0.6146 | 1.55 | 0.531 | 0.6367 | 0.4852 | 6.07 | 840,410.00 | -23.18 | -47.06 | -30.95 | -52.64 | 91.89 | -- | -36.40 | -268.59 | 2.55 | -3.31 | 0.6084 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -55.94m | 184.44m | 51.00 | -- | 0.7039 | -- | -- | -1.05 | -1.05 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | -22.89 | -- | -23.72 | -- | -- | -- | -- | -- | -- | -- | 0.1034 | -- | -- | -- | -22.20 | -- | -- | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -33.08m | 186.56m | 140.00 | -- | 24.12 | -- | -- | -1.29 | -1.29 | 0.00 | 0.1534 | 0.00 | -- | -- | 0.00 | -87.80 | -- | -140.92 | -- | -- | -- | -- | -- | -- | -28.75 | 0.6695 | -- | -- | -- | -11.06 | -- | -- | -- |
| Biomea Fusion Inc | 0.00 | -127.27m | 191.23m | 110.00 | -- | 1.41 | -- | -- | -3.57 | -3.57 | 0.00 | 3.77 | 0.00 | -- | -- | 0.00 | -90.54 | -- | -107.35 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -22.53m | 192.53m | 10.00 | -- | -- | -- | -- | -1.03 | -1.03 | 0.00 | -0.1181 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -272.15 | -- | -- | -- |
| Pyxis Oncology Inc | 16.15m | -57.80m | 192.57m | 51.00 | -- | 1.04 | -- | 11.93 | -1.39 | -1.39 | 0.368 | 3.13 | 0.0801 | -- | -- | 322,920.00 | -28.68 | -- | -30.64 | -- | 97.06 | -- | -358.00 | -- | -- | -- | 0.00 | -- | -- | -- | 38.87 | -- | -- | -- |
| Metagenomi Inc | -100.00bn | -100.00bn | 194.06m | 237.00 | -- | 0.7041 | -- | -- | -- | -- | -- | 7.36 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| Candel Therapeutics Inc | 0.00 | -37.37m | 195.50m | 42.00 | -- | 32.25 | -- | -- | -1.29 | -1.29 | 0.00 | 0.2037 | 0.00 | -- | -- | 0.00 | -75.90 | -- | -93.79 | -- | -- | -- | -- | -- | -- | -38.49 | 0.7674 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Coherus Biosciences Inc | 301.87m | -59.29m | 199.62m | 249.00 | -- | -- | -- | 0.6613 | -0.7801 | -0.7801 | 2.86 | -0.7211 | 0.5178 | 3.17 | 1.71 | 986,506.60 | -10.17 | -21.43 | -23.51 | -29.32 | 41.46 | 79.01 | -19.64 | -36.56 | 1.05 | -3.87 | 1.21 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Trevi Therapeutics Inc | 0.00 | -33.57m | 200.04m | 25.00 | -- | 2.71 | -- | -- | -0.338 | -0.338 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -34.47 | -47.39 | -38.08 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0017 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| Lineage Cell Therapeutics Inc | 8.00m | -23.66m | 200.15m | 75.00 | -- | 2.76 | -- | 25.01 | -0.1344 | -0.1344 | 0.0455 | 0.3836 | 0.0722 | -- | 57.16 | 106,706.70 | -21.32 | -19.53 | -24.82 | -22.59 | 91.88 | 89.13 | -295.30 | -370.88 | -- | -- | 0.0018 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
| XBiotech Inc | 0.00 | -30.74m | 200.41m | 92.00 | -- | 0.9574 | -- | -- | -1.01 | -1.01 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | -13.08 | 31.88 | -13.68 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0456 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Generation Bio Co | 9.96m | -169.06m | 202.25m | 174.00 | -- | 1.53 | -- | 20.30 | -2.56 | -2.56 | 0.1509 | 1.99 | 0.0278 | -- | 10.98 | 57,258.62 | -47.14 | -36.96 | -50.75 | -39.21 | -- | -- | -1,696.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
Data as of Jul 22 2024. Currency figures normalised to Metagenomi Inc's reporting currency: US Dollar USD
22.65%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Mar 2024 | 1.74m | 4.66% |
| Farallon Capital Management LLCas of 31 Mar 2024 | 1.34m | 3.59% |
| PFM Health Sciences LPas of 31 Mar 2024 | 1.27m | 3.38% |
| HHLR Advisors Ltd.as of 31 Mar 2024 | 777.77k | 2.08% |
| Millennium Management LLCas of 31 Mar 2024 | 747.55k | 2.00% |
| Citadel Advisors LLCas of 31 Mar 2024 | 723.90k | 1.93% |
| Eventide Asset Management LLCas of 31 Mar 2024 | 583.04k | 1.56% |
| Deep Track Capital LPas of 31 Mar 2024 | 466.23k | 1.24% |
| Pura Vida Investments LLCas of 31 Mar 2024 | 461.28k | 1.23% |
| Point72 Asset Management LPas of 31 Mar 2024 | 371.10k | 0.99% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
